MedAlliance has launched ORIGIN SC and ORIGIN NC, two high performance balloons for vessel preparation. These very much complement SELUTION SLR™, its novel sirolimus-eluting balloon per the company.
ORIGIN SC is a semi-compliant (SC) PTCA balloon with a very low crossing profile, making it an excellent choice for challenging lesions. ORIGIN SC offers one of the broadest portfolio of sizes available for an SC balloon, including 1.00 mm, 1.25 mm, 1.50 mm and 1.75 mm balloon diameters to treat very small vessels and complex cases.
ORIGIN NC is a non-compliant (NC) PTCA balloon, combining high pressure tolerance and controlled compliance with an optimal crossing profile for the most challenging cases. Origin NC’s minimal balloon longitudinal growth ensures focused dilatation force on the target lesion, minimizing the risk of damaging healthy tissue. ORIGIN NC also offers one of the lowest crossing profiles among all categories of PTCA balloon catheter currently available. It is particularly appropriate when facing tight stenoses in calcified, fibrotic lesions.
Drug-Eluting Balloons (DEBs) such as SELUTION SLR are designed to effectively deliver drug to the lesion site rather than dilate the vessel. This is why PTCA balloons designed for vessel preparation such as ORIGIN SC and ORIGIN NC are particularly appropriate in a pre-dilation role. These balloons, however, do not have to be used exclusively in conjunction with SELUTION SLR: they can be used on their own, for example to pre-dilate a vessel prior to stent implantation or to post-dilate a coronary stent to achieve accurate and controlled stent expansion.
“We are excited to be broadening our balloon portfolio with the ORIGIN range which complements our flagship DEB SELUTION SLR”, said Jeffrey B. Jump, Chairman and CEO of MedAlliance. “This is just the start of our product expansion program to vertically integrate high quality products for the benefit of patients around the world”.
MedAlliance’s DEB technology involves unique MicroReservoirs made from biodegradable polymer intermixed with the anti-restenotic drug sirolimus. These MicroReservoirs provide controlled and sustained release of the drug for up to 90 days1. Extended release of sirolimus from stents has been proven highly efficacious in both coronary and peripheral vasculatures. MedAlliance’s proprietary CAT™ (Cell Adherent Technology) enables the MicroReservoirs to be coated onto balloons and adhere to the vessel lumen when delivered via an angioplasty balloon.
SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary arterial disease in May 2020. It is now available in Europe and all other countries where the CE Mark is recognized.
